Hosted on MSN

Merus N.V.'s SWOT analysis: biotech firm's stock poised for growth amid clinical trials

Merus N.V. (NASDAQ:MRUS), a biotechnology company specializing in innovative antibody-based therapies with a market capitalization of $2.75 billion, has garnered significant attention from analysts ...
Insider Monkey

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May ...
Seeking Alpha

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical ...
Seeking Alpha

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length ...
Nasdaq

Merus N.V. Updates on Petosemtamab Trials and Financial Outlook for 2025 and Beyond

Merus N.V. announced progress on its clinical trials involving petosemtamab, designed for treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer ...
Nasdaq

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration ...